Long-Term Efficacy and Safety of Deutetrabenazine for Chorea in Huntington's Disease: Results From the ARC-HD Open-Label Study

被引：0
|
作者：
Frank, Samuel [1 ]
Testa, Claudia M. [2 ]
Stamler, David [3 ]
Kayson, Elise [4 ]
Oakes, David [4 ]
Vaughan, Christina [5 ]
Goldstein, Jody [4 ]
Whaley, Jacquelyn [4 ]
Davis, Matthew D.
Gordon, Mark Forrest [1 ]
Savolay, Juha-Matti [6 ]
机构：
[1] Teva Pharmaceut Ind Ltd, Frazer, PA USA
[2] Virginia Commonwealth Univ, Richmond, VA USA
[3] Alter Therapeut, San Francisco, CA USA
[4] Univ Rochester, Rochester, NY USA
[5] Univ Colorado, Aurora, CO USA
[6] Teva Pharmaceut Int, Basel, Switzerland
来源：
NEUROTHERAPEUTICS | 2020年 / 17卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
74
引用
收藏
页码：27 / 28
页数：2
相关论文
共 50 条
  • [1] The Safety of Deutetrabenazine for Chorea in Huntington Disease: An Open-Label Extension Study
    Samuel Frank
    Claudia Testa
    Mary C. Edmondson
    Jody Goldstein
    Elise Kayson
    Blair R. Leavitt
    David Oakes
    Christine O’Neill
    Christina Vaughan
    Jacquelyn Whaley
    Nicholas Gross
    Mark Forrest Gordon
    Juha-Matti Savola
    [J]. CNS Drugs, 2022, 36 : 1207 - 1216
  • [2] The Safety of Deutetrabenazine for Chorea in Huntington Disease: An Open-Label Extension Study
    Frank, Samuel
    Testa, Claudia
    Edmondson, Mary C.
    Goldstein, Jody
    Kayson, Elise
    Leavitt, Blair R.
    Oakes, David
    O'Neill, Christine
    Vaughan, Christina
    Whaley, Jacquelyn
    Gross, Nicholas
    Gordon, Mark Forrest
    Savola, Juha-Matti
    [J]. CNS DRUGS, 2022, 36 (11) : 1207 - 1216
  • [3] The long-term safety of deutetrabenazine for chorea in Huntington's disease
    Frank, S.
    Vaughan, C.
    Stamler, D.
    Oakes, D.
    Davis, M.
    Eberly, S.
    Kayson, E.
    Whaley, J.
    Goldstein, J.
    Testa, C.
    [J]. MOVEMENT DISORDERS, 2017, 32
  • [4] Alternative for reducing chorea in Huntington's disease (ARC-HD): Results from the Switch cohort
    Frank, S.
    [J]. MOVEMENT DISORDERS, 2015, 30 : S531 - S531
  • [5] Long-term safety of deutetrabenazine for the treatment of tardive dyskinesia: Results from an open-label, long-term study
    Anderson, K.
    Stamler, D.
    Davis, M.
    Factor, S.
    Hauser, R.
    Isojarvi, J.
    Jarskog, L.
    Jimenez-Shahed, J.
    Kumar, R.
    Ochudlo, S.
    Ondo, W.
    Fernandez, H.
    [J]. MOVEMENT DISORDERS, 2017, 32
  • [6] LONG-TERM SAFETY AND TOLERABILITY OF PRIDOPIDINE IN PATIENTS WITH HUNTINGTON'S DISEASE (HD): RESULTS OF THE MERMAIHD STUDY OPEN-LABEL EXTENSION
    Squitieri, F.
    Landwehrmeyer, B.
    Reilmann, R.
    Rosser, A.
    Garcia de Yebenes, J.
    Prang, A.
    Ivkovic, J.
    [J]. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2012, 83 : A56 - A57
  • [7] Alternatives for reducing chorea in Huntington disease, a long-term trial (ARC-HD): Updated week 8 results for the switch cohort
    Sung, V.
    Stamler, D.
    Claassen, D. O.
    [J]. MOVEMENT DISORDERS, 2016, 31 : S369 - S369
  • [8] DEUTETRABENAZINE: UPDATE ON FIRST TIME USE OF SD-809 IN HUNTINGTON'S DISEASE (FIRST-HD) AND ALTERNATIVE FOR REDUCING CHOREA IN HUNTINGTON'S DISEASE (ARC-HD)
    Testa, Claudia
    [J]. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2016, 87 : A101 - A101
  • [9] Deep brain stimulation for Huntington's disease: long-term results of a prospective open-label study
    Gonzalez, Victoria
    Cif, Laura
    Biolsi, Brigitte
    Garcia-Ptacek, Sara
    Seychelles, Anne
    Sanrey, Emily
    Descours, Irene
    Coubes, Christine
    de Moura, Ana-Maria Ribeiro
    Corlobe, Astrid
    James, Syril
    Roujeau, Thomas
    Coubes, Philippe
    [J]. JOURNAL OF NEUROSURGERY, 2014, 121 (01) : 114 - 122
  • [10] Sustained Improvements in Chorea Associated With Huntington Disease With Once-Daily Valbenazine: Interim Results From a Long-Term Open-Label Study
    Stimming, Erin Furr
    Claassen, Daniel O.
    Kayson, Elise
    Goldstein, Jody
    Hinton, Sean C.
    Klepitskaya, Olga
    Zhang, Hui
    Liang, Grace
    Sheth, Bijal
    Haubenberger, Dietrich
    [J]. NEUROPSYCHOPHARMACOLOGY, 2023, 48 : 296 - 296
12345